Catestatin Peptide Reduces Tau and Amyloid in Preclinical Study

Preclinical Research Evaluates Catestatin Peptide for Neurodegeneration

A study published in Molecular Therapy reports that a naturally occurring peptide called catestatin (CST) reduced abnormal protein deposits in mice. Researchers at the University of California San Diego (UC San Diego) School of Medicine led the project. The work evaluated neuroinflammation, memory, and motor function.

Most experimental therapies focus on a single biological target. Neurodegeneration, however, involves several overlapping dysfunctions. In this mouse model, catestatin addressed multiple diseased pathways simultaneously rather than isolating one mechanism.

Observed Effects on Amyloid, Tau, and Neuroinflammation in Mice

Catestatin reduced the accumulation of both tau and amyloid proteins in mouse brain tissue. The compound also decreased markers of chronic neuroinflammation. These changes translated to physical gains.

Mice treated with the peptide demonstrated better cognitive performance and motor coordination during behavioral testing. The formal paper indicates that catestatin acts partly through adrenergic inhibition. This adrenergic pathway altered how brain cells responded to persistent neurological stress. Lead author Suborno Jati noted that targeting several pathways may help neurons resist complex degeneration.

Metabolic Roles of Catestatin and Cellular Energy Use

Catestatin is a peptide fragment cleaved from chromogranin A (CgA). Chromogranin A regulates the packaging and secretion of neurotransmitters and hormones. Earlier research connected catestatin to metabolic control, immune signaling, and cardiovascular health.

The researchers are now studying how the peptide alters brain energy use. Neurons face severe metabolic stress during neurodegenerative disease. Supporting cellular bioenergetics could help brain cells survive ongoing oxidative and structural strain.

Study Limitations and Commercial Conflicts of Interest

All reported findings are preclinical. Mice provide useful initial models, but animal biology does not always match human pathology. The investigative team must complete extensive toxicology and safety testing before human clinical trials can begin. Key questions remain about human safety, proper dosing schedules, and biological stability.

Readers should also consider the financial ties behind the project. Senior author Sushil K. Mahata founded CgA Therapeuticals Inc. and co-founded Siraj Therapeutics. Mahata and Jati also hold intellectual property filings covering these catestatin discoveries.

• The study examined mice, meaning clinical efficacy and safety in humans are unproven.
• Optimal dosing, bioavailability, and blood-brain barrier transport remain unknown.
• Key investigators hold patents and commercial interests in catestatin-related drug development.